SinoPharm CNBG Wuhan Institute of Biological Products Co., Ltd’s F61, a recombinant broad-spectrum novel coronavirus monoclonal antibody (mAb), has received clinical trial approval from the National Medical Products Administration (NMPA).
Development and Research
F61 was co-developed by Yang Xiaoming’s team with CNBG and Liang Mifang’s team from the Chinese Center for Disease Control and Prevention. The antibody was isolated and screened from mononuclear cells of recovered COVID-19 patients using phage display technology.
Efficacy Against Variants
Research shows that F61 exhibits high neutralizing activities against the prototype strain of SARS-CoV-2 and major global variants, including all subtypes (BA.1, BA.1.1, BA.2, BA.3, and BA.4/5) of the prevalent Omicron variant.
Preventive Use
Both teams are actively developing F61 nasal spray for preventive applications.-Fineline Info & Tech
